The best of R&I and around the web, handpicked by our editors.
White papers, service directory and conferences for the R&I community.
Web replica of the print magazine.
This year 6 brokers were selected as Pharmaceuticals Power Brokers. An additional five were named finalists.
The pandemic underscored the dangers of lengthy biotech and pharma supply chains, but there are strategies for better quality control transparency.
In the evolving clinical trials space, independent insurance agents play a key role in helping life sciences firms mitigate new risks.
This year, 6 brokers from across the brokerage field were named as the 2023 Pharmaceuticals Power Broker winners. An additional three brokers were named as finalists.
Digital transformation, clinical trials, climate change and product recalls are among the top risks and opportunities facing the life sciences sector over the next several years.
This year, brokers from across the brokerage field were named as the 2022 Pharmaceuticals Power Broker winners. An additional brokers were named as finalists.
Many thought leaders accurately predicted that the COVID-19 pandemic would not have a negative impact on workers’ compensation claims outcomes. But from a statistical perspective, the pandemic did warp workers’ comp pharmacy data.
Six commercial insurance brokers in the pharmaceutical sector were named 2021 Power Brokers. One additional broker was named a finalist.
The opioid misuse crisis continues to negatively impact the lives of patients while costing our health care system billions of dollars. This is why it still deserves our focus.
From whether or not employers can mandate a vaccine to the potential workers’ comp implications, here’s what businesses should be watching as the COVID-19 vaccine rolls out.
A new report concluded that COVID-19 has led to increased opioid abuse, medical marijuana legislation and drugs delivered by mail.
Despite regulation meant to curb abuse of physician dispensing, it’s still a common practice and presents both safety and financial risks.
Insurers blame ‘pay-for-delay’ for skyrocketing drug prices, but manufacturers insist settlements help control costs.
The search for a COVID-19 vaccine is on. Hopefully, advancements in artificial intelligence will make the time required to produce a vaccine shorter.
This year, six brokers from across the brokerage field were named as the 2020 Pharmaceuticals Power Broker winners. An additional two brokers were named as finalists.
Silvia Sacalis of Healthesystems details the different aspects of holistic care for injured workers and why each is important for a successful return-to-work.
The poisonous actions of pharma companies peddling painkillers are a social scourge that cannot be accepted.
Pharmaceutical companies and their insurers should brace themselves as the opioid litigation rages ahead.
A new decision out of Texas aims to hold PBMs accountable for their role in perpetuating the epidemic. Other municipalities are likely to follow suit.
Lawsuits against drug makers may be necessary, but to what degree do they aid addicted injured workers?